findmyKOL
Clinical trialNCT04023019RecruitingObservational

Treatment of Hemophilia A Patients With FVIII Inhibitors

SponsorEmory UniversityEnrollment120Hemophilia A
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a non-interventional, multicenter, observational, international study in male persons with haemophilia A who have developed inhibitors to any replacement coagulation factor VIII (FVIII) product. The purpose of the study is to capture different approaches in the management of persons with haemophilia A and FVIII inhibitors, document current immune tolerance induction approaches, and evaluate the efficacy and safety of immune tolerance induction, including the combination of FVIII and emicizumab. Patients will be assigned to 1 of 3 groups based on the treatments they receive, and may switch to another group if their treatment is changed. Participants will be followed after a maximum observational period of 5 years.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Germany
  • Hzrm Hämophilie-Zentrum Rhein Main

    Mörfelden-Walldorf, Germany

    Carmen Escuriola-Ettingshausen, MD
    Recruiting
United States
  • Arthur M. Blank Hospital

    Atlanta, Georgia, United States

    Robert Sidonio, MD, MSc
    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Activated prothrombin complex concentrateEmicizumabNuwiqOctanateFactor VIIaWilate
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
17 Mar 2020
Primary completion
31 Dec 2028
Completion
30 Jun 2029
Last update posted
5 Sept 2025
Registered enrollment
120
Registry id
NCT04023019
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.